# Sichuan Kelun-Biotech Biopharmaceutical trials: 55 (2026)

ClinicalTrials.gov lists 55 trials with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. as lead sponsor, 33 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: 55 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sichuan-kelun-biotech-biopharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 55
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 55, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 2, 2026 | NCT07854509 | A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854509) |
| September 10, 2026 | NCT07814066 | A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Pancreatic Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814066) |
| August 19, 2026 | NCT07774624 | Study of SKB103 in HER2-negative Breast Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Breast Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774624) |
| July 28, 2026 | NCT07732023 | A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Asthma (Diagnosis) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732023) |
| July 14, 2026 | NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700667) |
| July 13, 2026 | NCT07697586 | SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | NSCLC | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697586) |
| June 25, 2026 | NCT07668154 | A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | HNSCC | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668154) |
| June 3, 2026 | NCT07622186 | A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622186) |
| May 27, 2026 | NCT07609667 | SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Gastroesophageal Junction Adenocarcinoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609667) |
| May 14, 2026 | NCT07586943 | SKB118 Injection in Advanced Solid Tumors | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586943) |
| May 4, 2026 | NCT07564466 | A Study of SKB571 in Participants With Gastrointestinal Tumors | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Gastrointestinal Tumors | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564466) |
| April 22, 2026 | NCT07545265 | SKB565 for Injection in Advanced Solid Tumors | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545265) |
| March 23, 2026 | NCT07488065 | A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Atopic Dermatitis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488065) |
| March 10, 2026 | NCT07459998 | SKB103 for Injection in Advanced Solid Tumors | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459998) |
| March 4, 2026 | NCT07448922 | A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Advanced Gynecological Malignancies | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448922) |
| February 2, 2026 | NCT07380386 | SKB105 for Injection in Advanced Solid Tumors | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07380386) |
| January 14, 2026 | NCT07341100 | Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Active not recruiting | Ovarian Epithelial Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341100) |
| January 9, 2026 | NCT07329322 | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07329322) |
| January 7, 2026 | NCT07324629 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Thymic Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07324629) |
| December 29, 2025 | NCT07308106 | A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Non-small Lung Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308106) |
| December 23, 2025 | NCT07299825 | A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Her 2 Positive Breast Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299825) |
| December 22, 2025 | NCT07296809 | SKB500 Combinations in Patients With Small Cell Lung Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296809) |
| November 17, 2025 | NCT07230405 | A Phase II Study of SKB571 in Patients With Lung Cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Lung Cancer (Non-Small Cell) | 295 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230405) |
| July 25, 2025 | NCT07087197 | A Study of SKB107 in Advanced Solid Tumors With Bone Metastases | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Metastatic Solid Tumors | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07087197) |
| July 17, 2025 | NCT07071337 | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Metastatic Breast Cancer | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07071337) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 6 |
| Phase 2 | 23 |
| Phase 3 | 12 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 29 |
| Active not recruiting | 11 |
| Completed | 9 |
| Not yet recruiting | 4 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Breast Neoplasms | 4 |
| Colorectal Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Nasopharyngeal Carcinoma | 2 |
| Recurrence | 2 |
| Neoplasm Metastasis | 2 |
| Thyroid Diseases | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Digestive System Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Dermatitis, Atopic | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Small Cell Lung Carcinoma | 1 |
| Thymoma | 1 |
| Lung Neoplasms | 1 |
| Asthma | 1 |
| Disease | 1 |
| Alopecia Areata | 1 |
| Hypotrichosis | 1 |
| Hair Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Tiki bars in the United States](https://specstream.ai/data/businesses/tiki-bars/united-states)
- [Emergency and urgent care facilities in the United States](https://specstream.ai/data/businesses/emergency-and-urgent-care-facilities/united-states)
- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
- [Business financing companies in the United States](https://specstream.ai/data/businesses/business-financing-companies/united-states)
- [Masonry and concrete contractors in the United States](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/united-states)
